Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anti-neuroinflammation Agent 1 effectively modulates BV2 microglia cell polarization, shifting from an M1 to an M2 phenotype [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Anti-neuroinflammation Agent 1 effectively modulates BV2 microglia cell polarization, shifting from an M1 to an M2 phenotype [1]. |
In vitro | Anti-neuroinflammation agent 1 (BMP 29) demonstrated enhanced anti-neuroinflammatory activity in vitro without toxicity to BV2 microglial cells. In lipopolysaccharide (LPS)-stimulated BV2 microglia, the agent significantly reduced the number of M1 phenotype microglia while markedly increasing the M2 phenotype. Additionally, it substantially decreased the secretion of pro-inflammatory cytokines (IL-18, IL-1β, TNF-α) but increased the secretion of the anti-inflammatory cytokine (IL-10) in LPS-induced BV2 cells. Anti-neuroinflammation agent 1 also inhibited the formation of the NLRP3 inflammasome and downregulated the expression of the M2 isoform of pyruvate kinase in LPS-stimulated BV2 microglial cells [1]. |
In vivo | In mice, Anti-neuroinflammation Agent 1 (BMP 29) mitigates cuprizone-induced inflammation and demyelination by reducing the expression of inducible nitric oxide synthase, while simultaneously increasing the expression of CD206 [1]. |
Molecular Weight | 523.86 |
Formula | C22H20ClF6N3O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Anti-neuroinflammation agent 1 Immunology/Inflammation NOD-like Receptor (NLR) inhibitor inhibit